NeuroOne Reports 163% Revenue Growth Driven by Epilepsy Treatment Technology
NeuroOne Medical Technologies announced record preliminary product revenue of $9.1 million for fiscal 2025, representing 163% growth driven by increased adoption of its OneRF Ablation system for epilepsy treatment.
NeuroOne Medical Technologies Corporation reported preliminary unaudited product revenue growth of 163% to a record $9.1 million for the fiscal year ended September 30, 2025. The medical technology company, which trades on Nasdaq under the symbol NMTC, saw substantial growth compared to $3.5 million in product revenue during fiscal 2024. The company also reported preliminary cash and cash equivalents of $6.6 million as of September 30, 2025.
Chief Executive Officer Dave Rosa attributed the strong performance to expanded customer interest and positive outcomes with the company's OneRF Ablation system for patients suffering from seizures associated with epilepsy. "We believe we are well positioned to expand use of the OneRF technology platform," Rosa stated in the company's announcement. The complete financial results for the quarter are expected to be announced in December 2025.
The company will host a virtual investor webinar to discuss its business operations and recent updates. The event, scheduled for October 7, 2025, at 8:30 a.m. Eastern Standard Time, will feature presentations from both CEO Dave Rosa and Chief Financial Officer Ron McClurg. Interested parties can access the webcast through the company's website or by dialing the provided numbers.
NeuroOne's technology focuses on improving surgical care options and outcomes for patients suffering from neurological disorders. The company develops and commercializes minimally invasive and high-definition solutions for EEG recording, brain stimulation and ablation solutions. These technologies target conditions including epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries.
The preliminary financial information released by NeuroOne remains subject to completion of accounting and interim review procedures and may be subject to adjustment. Management has prepared this information in good faith on a consistent basis with prior periods, but prospective investors should exercise caution in relying on this preliminary data. The company emphasized that this information should not be viewed as a substitute for full financial statements prepared in accordance with United States generally accepted accounting principles.
The significant revenue growth reflects increasing adoption of NeuroOne's medical technologies in the neurological treatment market. As the company continues to expand its technology platform, the financial results suggest growing market acceptance of its solutions for complex neurological conditions. The upcoming investor webinar will provide additional context about the company's business model and recent milestone achievements.